Serving 500+ biopharmaceutical companies globally:
Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing
Serving 500+ biopharmaceutical companies globally:
Generated: September 26, 2017
What is the competitive landscape for FOREST LABS LLC, and what generic alternatives to FOREST LABS LLC drugs are available?
FOREST LABS LLC has ten approved drugs.| Patents: | 35 |
| Tradenames: | 9 |
| Ingredients: | 8 |
| NDAs: | 10 |
Export unavailable in trial.
Subscribe for complete access.
Export unavailable in trial.
Subscribe for complete access.
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
nebivolol hydrochloride and valsartan | Tablets | 5 mg/80 mg | BYVALSON | 6/9/2017 |
memantine hydrochloride extended-release and donepezil hydrochloride | Capsules | 7 mg/10 mg | NAMZARIC | 9/26/2016 |
memantine hydrochloride extended-release and donepezil hydrochloride | Capsules | 21 mg/10 mg | NAMZARIC | 9/23/2016 |
linaclotide | Capsules | 145 mcg and 290 mcg | LINZESS | 8/30/2016 |
memantine hydrochloride extended-release and donepezil hydrochloride | Capsules | 14 mg/10 mg and 28 mg/10 mg | NAMZARIC | 5/18/2015 |
vilazodone hydrochloride | Tablets | 10 mg, 20 mg, and 40 mg | VIIBRYD | 1/21/2015 |
bismuth subcitrate potassium, metronidazole, and tetracycline hydrochloride | Capsules | 140 mg/125 mg/ 125 mg | PYLERA | 8/12/2014 |
memantine hydrochloride | Extended-release Capsules | 7 mg, 14 mg, 21 mg, and 28 mg | NAMENDA XR | 8/16/2013 |
asenapine maleate | Sublingual Tablets | 5 mg and 10 mg | SAPHRIS | 8/13/2013 |
memantine hydrochloride | Extended-release Capsules | 7 mg, 14 mg, 21 mg | NAMENDA XR | 6/17/2013 |
memantine hydrochloride | Extended-release Capsules | 28 mg | NAMENDA XR | 6/12/2013 |
memantine hydrochloride | Extended-release Capsules | 7 mg, 14 mg, 21 mg, and 28 mg | NAMENDA XR | 6/10/2013 |
mesalamine | Suppository | 1000 mg | CANASA | 5/24/2013 |
memantine hydrochloride | Tablets | 5 mg and 10 mg | NAMENDA | 10/16/2007 |
For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.
The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.
| Patent No. | Title | Estimated Patent Expiration | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 9,624,204 | Polymorphic forms of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl) piperazine hydrochloride | ► Subscribe | |||||||||||||
| 7,772,188 | Methods and compositions for the treatment of gastrointestinal disorders | ► Subscribe | |||||||||||||
| 7,541,384 | Mesalamine suppository | ► Subscribe | |||||||||||||
| 7,381,726 | Polymorphic forms of 1-'4-(5-cyanoindol-3-yl)butyl-4-(2-carbamoylbenzofuran-5-yl)piperazine hydrochloride | ► Subscribe | |||||||||||||
| 2,014,073,571 | ► Subscribe | ||||||||||||||
| 8,927,552 | Polymorphic forms of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl)piperazine hydrochloride | ► Subscribe | |||||||||||||
| 7,619,007 | Method and composition for administering an NMDA receptor antagonist to a subject | ► Subscribe | |||||||||||||
| 8,318,744 | Polymorphic forms of 1-'4-(5-cyanoindol-3-yl) butyl-4-(2-carbamoylbenzofuran-5-yl)piperazine hydrochloride | ► Subscribe | |||||||||||||
| 8,921,375 | Polymorphic forms of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl) piperazine hydrochloride | ► Subscribe | |||||||||||||
| 7,910,546 | Methods and compositions for the treatment of gastrointestinal disorders | ► Subscribe | |||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.
| Country | Document Number | Estimated Expiration | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| World Intellectual Property Organization (WIPO) | 2006130174 | ► Subscribe | |||||||||||||
| Portugal | 1911763 | ► Subscribe | |||||||||||||
| Canada | 2451028 | ► Subscribe | |||||||||||||
| Canada | 2558050 | ► Subscribe | |||||||||||||
| African Regional IP Organization (ARIPO) | 200704273 | ► Subscribe | |||||||||||||
| Slovenia | EP1911763 | ► Subscribe | |||||||||||||
| Canada | 2569881 | ► Subscribe | |||||||||||||
| Canada | 2315408 | ► Subscribe | |||||||||||||
| China | 102970971 | ► Subscribe | |||||||||||||
| Australia | 2004210161 | ► Subscribe | |||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws,
it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2013 00026 | Denmark | ► Subscribe | |||||||||||||
| 0594 | Netherlands | ► Subscribe | PRODUCT NAME: LINACLOTIDE; REGISTRATION NO/DATE: EU/1/12/801/001-004 20121126 | ||||||||||||
| 2013014 | Lithuania | ► Subscribe | PRODUCT NAME: LINACLOTIDUM; REGISTRATION NO/DATE: EU/1/12/801/001 - EU/1/12/801/004 20121126 | ||||||||||||
| 00594 | Netherlands | ► Subscribe | PRODUCT NAME: LINACLOTIDE; REGISTRATION NO/DATE: EU/1/12/801/001-004 20121126 | ||||||||||||
| 00593 | Netherlands | ► Subscribe | PRODUCT NAME: LINACLOTIDE; REGISTRATION NO/DATE: EU/1/12/801/001-004 20121126 | ||||||||||||
| C/GB02/046 | United Kingdom | ► Subscribe | PRODUCT NAME: MEMANTINE AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS; REGISTERED: UK EU/1/02/219/001 20020515; UK EU/1/02/219/002 20020515; UK EU/1/02/219/003 20020515; UK EU/1/02/219/004 20020515; UK EU/1/02/219/005 20020515; UK EU/1/02/219/006 20020515 | ||||||||||||
| 90024-6 | Sweden | ► Subscribe | PRODUCT NAME: LINAKLOTID; REG. NO/DATE: EU/1/12/801/001 20121126 | ||||||||||||
| 201 | Luxembourg | ► Subscribe | PRODUCT NAME: LINACLOTIDE ET TOUTE FORME THERAPEUTIQUE EQUIVALENTE DE CELUICI,PROTETE PAR LE BREVET DE BASE,Y COMPRIS DES SELS PHARMACEUTIQUEMENT ACCEPTABLES | ||||||||||||
| C/GB97/023 | United Kingdom | ► Subscribe | PRODUCT NAME: DONEPEZIL, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, INCLUDING THE HYDROCHLORIDE; REGISTERED: UK PL 10555/0006 19970214; UK PL 10555/0007 19970214 | ||||||||||||
| C/GB96/048 | United Kingdom | ► Subscribe | PRODUCT NAME: NEBIVOLOL, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT OR HYDRATE; REGISTERED: NL RVG/19317 19951018; UK 00242/0309 19960509 | ||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||
Export unavailable in trial.
Subscribe for complete access.
Serving 500+ biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Follow DrugPatentWatch:
Join the 22,768 others who get our Drug Patent Expiration Alerts:
